Marksans Pharma Ltd. — Capital/Financing Update 2023

Feb 13, 2023

==> picture [224 x 69] intentionally omitted <==

----- Start of picture text -----

·t·
Marksans Pharma Ltd.
----- End of picture text -----

Date: 13[th] February, 2023

BSE Limited Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404

National Stock Exchange of India Limited Listing Department Exchange Plaza, C-l, Block-G, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051. Symbol: MARKSANS

Sub: Statement on Deviation or Variation of funds raised through Preferential Issue of Convertible Warrants

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMDl/162/2019 dated December 24, 2019, we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated 15th June, 2021.

Accordingly, a Nil Statement of Deviation, duly reviewed by the Audit Committee of the Company, for the Quarter ended 31 st December, 2022 is given in "Annexure A".

Yours faithfully, For Marksans Pharma Limited

HARSHAVARD Digitally signed by HARSHAVARDHAN HAN PANIGRAHI Date: 2023.02.13 PANIGRAHI 17:24:20 +05'30'

Harshavardhan Panigrahi Company Secretary

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 224001 2000 • Fax: +91-224001 2011 E-mail: info@marksanspharma.com

Statement of Deviation / Variation in utilisation of funds raised
Name of listed entity Marksans Pharma Limited
Mode of Fund Raisine: Preferential Issue
Date of Raising Funds 20.07.2021
Amount Raised Rs. 93,09,99,994
Report filed for quarter ended 31slDecember, 2022
Monitorine: Ae:ency Not Applicable
Monitorine: Ae:ency Name, if applicable Not Applicable Is there a Deviation / Variation in use offunds raised No
If yes, whether the same is pursuant to change in terms Not Applicable of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval Not Applicable Explanation for the Deviation / Variation Not Applicable Comments of the Audit Committee after review Nil
Comments of the auditors, if any Nil

Objects for which funds have been raised and where there has been a deviation, in the following table

table
Original Object	Modified Object, if any	Original Allocation	Modified allocation , if any	Funds utilised till 31st December, 2022	Amount of deviation/ variation for the quarter according to applicable object	Remarks ifany
The proceeds of the preferential issue are proposed to be used to strengthen the capital base and toenhance long term financial resources of the Company in order to fund expansion program of the Company.	None	Rs. 93,09,99,994	-	Rs. 29,67,87,500	-	No deviations

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or (b) Deviation in the amount offunds actually utilized as against what was originally disclosed or (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

Harshavardhan Panigrahi Company Secretary & Compliance Officer